Central nervous system metastases in breast cancer patients administered trastuzumab

被引:46
作者
Duchnowska, R [1 ]
Szczylik, C [1 ]
机构
[1] Mil Inst Med, Dept Oncol, PL-00909 Warsaw, Poland
关键词
breast cancer; HER2/neu; trastuzumab; blood-brain barrier; brain metastases;
D O I
10.1016/j.ctrv.2005.04.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Amplification or over-expression of the HER2/neu receptor is present in 20-30% of invasive breast cancers and in 60% of intraductal breast carcinomas. Patients with HER2/neu gene aberrations have more aggressive disease, frequent disease recurrence and a shorter survival. Trastuzumab (herceptin) is a monoclonal antibody selectively directed against the HER2/neu receptor. The addition of trastuzumab to chemotherapy in HER2/neu-positive advanced breast cancer patients has increased complete and partial response rates, and prolonged time to progression and overall survival. However, a relatively common failure site in patients administered trastuzumab is the central nervous system (CNS). CNS metastases in these patients seem to develop despite responses achieved in extracerebral sites. This pattern of failure has mainly been attributed to the lack of trastuzumab penetration to the CNS owing to the high molecular weight (145 kDa) of this molecule. Additionally, increased risk of CNS relapse may be associated with improved systemic control of extracerebral metastases and prolonged survival without brain protection (a sanctuary site). Finally, it was postulated that HER2/neu over-expression and/or amplification might predispose to brain metastases. The aim of this article is to discuss the pathophysiotogy of this phenomenon and its clinical implications. (C) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:312 / 318
页数:7
相关论文
共 89 条
  • [51] Nichols DW, 2002, ANN CLIN LAB SCI, V32, P3
  • [52] THE CHOICE OF TREATMENT OF SINGLE BRAIN METASTASIS SHOULD BE BASED ON EXTRACRANIAL TUMOR-ACTIVITY AND AGE
    NOORDIJK, EM
    VECHT, CJ
    HAAXMAREICHE, H
    PADBERG, GW
    VOORMOLEN, JHC
    HOEKSTRA, FH
    TANS, JTJ
    LAMBOOIJ, N
    METSAARS, JAL
    WATTENDORFF, AR
    BRAND, R
    HERMANS, J
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (04): : 711 - 717
  • [53] A RANDOMIZED TRIAL OF SURGERY IN THE TREATMENT OF SINGLE METASTASES TO THE BRAIN
    PATCHELL, RA
    TIBBS, PA
    WALSH, JW
    DEMPSEY, RJ
    MARUYAMA, Y
    KRYSCIO, RJ
    MARKESBERY, WR
    MACDONALD, JS
    YOUNG, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (08) : 494 - 500
  • [54] Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer:: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
    Pauletti, G
    Dandekar, S
    Rong, HM
    Ramos, L
    Pong, HJ
    Seshadri, R
    Slamon, DJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (21) : 3651 - 3664
  • [55] Pegram M. D., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P602
  • [56] Trastuzumab in CSF
    Pestalozzi, BC
    Brignoli, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (11) : 2350 - 2351
  • [57] Pestalozzi BC, 2001, J CLIN ONCOL, V19, P3298
  • [58] LOCALIZATION OF THE HUMAN ERB-2 GENE ON NORMAL AND REARRANGED CHROMOSOMES 17 TO BANDS Q12-21.32
    POPESCU, NC
    KING, CR
    KRAUS, MH
    [J]. GENOMICS, 1989, 4 (03) : 362 - 366
  • [59] HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
    Press, MF
    Bernstein, L
    Thomas, PA
    Meisner, LF
    Zhou, JY
    Ma, YL
    Hung, G
    Robinson, RA
    Harris, C
    ElNaggar, A
    Slamon, DJ
    Phillips, RN
    Ross, JS
    Wolman, SR
    Flom, KJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (08) : 2894 - 2904
  • [60] INFLUENCE OF RADIATION ON THE BLOOD-BRAIN-BARRIER AND OPTIMUM TIME OF CHEMOTHERAPY
    QIN, DX
    ZHENG, R
    TANG, J
    LI, JX
    HU, YH
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (06): : 1507 - 1510